Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
暂无分享,去创建一个
Hiroyuki Takahashi | S. Egawa | H. Sasaki | M. Kido | H. Kuruma | M. Aoki | K. Miki | T. Kimura | R. Tabata
[1] F. Calvo,et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[2] Tomoki Tanaka,et al. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients. , 2015, Brachytherapy.
[3] J. Asaumi,et al. Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer: comparison between EORTC prostate cancer radiotherapy guideline, RTOG0815 protocol and actual anatomy , 2014, Radiation oncology.
[4] Jiming Liu,et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.
[5] N. Shigematsu,et al. Assessing protection against radiation exposure after prostate (125)I brachytherapy. , 2014, Brachytherapy.
[6] Hiroyuki Takahashi,et al. Mid‐term outcome of permanent prostate iodine‐125 brachytherapy in Japanese patients , 2014, International journal of urology : official journal of the Japanese Urological Association.
[7] R. Stock,et al. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes , 2013, BJU international.
[8] N. Keating,et al. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? , 2013, European urology.
[9] Howard Pai,et al. Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer , 2013, Cancer.
[10] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[11] B. Dubray,et al. Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Unger,et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.
[13] Hiroyuki Takahashi,et al. Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial , 2010, BMC Cancer.
[14] K. Wallner,et al. Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer? , 2010, Oncology.
[15] W. J. Morris,et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. , 2009, Urology.
[16] M. Kattan,et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. , 2009, International journal of radiation oncology, biology, physics.
[17] Michael W Kattan,et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. , 2007, International journal of radiation oncology, biology, physics.
[18] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[19] Barry S Rosenstein,et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.
[20] M. Piérart,et al. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991. , 2004, European journal of cancer.
[21] M. Piérart,et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. , 2004, European journal of cancer.
[22] Jacques Bernier,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.
[23] M. Benson,et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. , 2000, The Journal of urology.
[24] T. Matsuda,et al. Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan , 1999, Prostate Cancer and Prostatic Diseases.
[25] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[26] R. Stock,et al. A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.
[27] G. Tirelli,et al. Prognosis of oral cancer: a comparison of the staging systems given in the 7th and 8th editions of the American Joint Committee on Cancer Staging Manual. , 2018, The British journal of oral & maxillofacial surgery.
[28] R. Stock,et al. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center. , 2014, Urologic oncology.
[29] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.